Life Sciences
Top stories summarized by our editors
9/20/2019

Fancy's new campaign for the "It's On Us" initiative, launched five years ago by the Obama administration, features powerful public service announcements showing college students telling their very personal stories about sexual assault. "Witnessing the courage these young people showed in telling their stories and opening their own wounds so that others won't be hurt resonated with truth and hope and literally brought us all to tears on set -- a rare moment in an advertising lifetime," says Fancy's Erica Fite.

More Summaries:
fancy, Obama administration
9/20/2019

Rhythm Pharmaceuticals' setmelanotide was granted orphan drug status as a treatment for the rare genetic disorder Bardet-Biedl syndrome. The drug is being tested in a late-stage trial and enrollment completion is expected the second half of this year.

Full Story:
Seeking Alpha
9/20/2019

University of California President Janet Napolitano, the first woman to lead the university system, announced she will resign next August. Napolitano boosted enrollment, expanded community college transfers and oversaw the launch of the UC Cancer Consortium, which conducts more than 1,000 clinical trials each year, but her tenure has not been without controversy.

9/20/2019

Testing of Turning Point Therapeutics' repotrectinib, a tyrosine kinase inhibitor for lung cancer, has been positive, and two other drugs are advancing to clinical testing, CEO Athena Countouriotis says. A follow-on offering to Turning Point's IPO raised $202.5 million, buffering the company from negative market forces, and former Goldman Sachs investment banker Yi Larson, who assisted with the IPO, has come on board as chief financial officer.

9/20/2019

Collagen supplements have been shown to ease arthritis and encourage wound healing, but trends like adding collagen powder to coffee are probably useless wastes of money, writes assistant professor of microbiology Brooke Russell, whose lab is working on a way to synthesize collagen without sourcing it from animals. Eating certain foods like berries and leafy green vegetables is the best way to boost collagen, and those who prefer supplements "should use a refrigerated, liquid collagen or collagen powder mixed into a cold beverage," Russell writes.

Full Story:
The Conversation (US)
9/20/2019

The hesitance of many women to use public restrooms, especially to defecate, can cause physical problems and springs from being taught at a very young age to keep their bodily functions private, says psychologist Nicholas Haslam. "At one level it's an association of women with purity," Haslam said. "At another it's a double standard applied to hygiene and civility, where the weight falls disproportionately on women to be clean, odorless and groomed."

More Summaries:
Nicholas Haslam
9/20/2019

Poet Anne Boyer weaves the story of physical and psychological mutilation she experienced before, during and after treatment for breast cancer in her new book, The Undying. The stigma once attached to breast cancer is gone, replaced by pink ribbons and social pressure to endure "the calamity of medicine" with a brave face and gratitude, Boyer says.

Full Story:
National Public Radio
More Summaries:
Anne Boyer
9/20/2019

Jaye Gardiner, a postdoctoral researcher studying pancreatic cancer and cofounder of JKX Comics, was named an American Association for the Advancement of Science IF/THEN ambassador. Gardiner draws portraits of a diverse array of scientists for Twitter using #UniqueScientists, and in her role as AAAS ambassador will mentor middle-school-age girls.

Full Story:
Technical.ly
More Summaries:
Jaye Gardiner, AAAS, JKX Comics, Twitter
9/20/2019

The UK's National Institute for Health and Care Excellence has recommended the use of Takeda's Takhzyro, or lanadelumab, for the treatment of the rare disease hereditary angioedema. NICE has issued a guidance document that indicates Takhzyro, a subcutaneous injectable treatment, may be used to prevent recurrent attacks in patients aged 12 and older with type I/II HAE and will be available through the National Health Service in Wales and England.

Full Story:
PMLive (UK)
9/20/2019

After the FDA granted Merck's Ebola vaccine candidate V920 priority review status, the company announced plans to manufacture 650,000 more doses over the next 6 to 18 months in order to meet the current demand for its Ebola vaccine being used in the Democratic Republic of Congo​ to combat an ongoing outbreak.

Full Story:
BioPharmaReporter
More Summaries:
Ebola, FDA